EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Non-Hemadsorbing Live-Attenuated Virus Vaccine Candidate Protects Pigs against the Contemporary Pandemic Genotype II African Swine Fever Virus

Quang Lam Truong iD, Lihua Wang iD, Tuan Anh Nguyen, Hoa Thi Nguyen, Anh Dao Le, Giap Van Nguyen iD, Anh Thi Vu, Phuong Thi Hoang, Trang Thi Le, Huyen Thi Nguyen, Hang Thu Thi Nguyen, Huong Lan Thi Lai iD und 8 weitere

Viruses · 2024

DOI: 10.3390/v16081326 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2024. Verfasst von Quang Lam Truong und 19 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Veterinary Biotechnology, Faculty of Veterinary Medicine, Vietnam National University of Agriculture, Gia Lam, Ha Noi 12406, Vietna…. Hauptthemen laut MEDLINE: African Swine Fever Virus, Vaccines, Attenuated, African Swine Fever, Viral Vaccines. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Vietnam Ministry of Science and Technology, National Bio and Agro-Defense Facility Transition Fund, the USDA National Institute of Food and Agriculture, USDA ARS Non-Assistance Cooperative Agreements.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

African swine fever (ASF) is a highly contagious and severe hemorrhagic transboundary swine viral disease with up to a 100% mortality rate, which leads to a tremendous socio-economic loss worldwide. The lack of safe and efficacious ASF vaccines is the greatest challenge in the prevention and control of ASF. In this study, we generated a safe and effective live-attenuated virus (LAV) vaccine candidate VNUA-ASFV-LAVL3 by serially passaging a virulent genotype II strain (VNUA-ASFV-L2) in an immortalized porcine alveolar macrophage cell line (3D4/21, 50 passages). VNUA-ASFV-LAVL3 lost its hemadsorption ability but maintained comparable growth kinetics in 3D4/21 cells to that of the parental strain. Notably, it exhibited significant attenuation of virulence in pigs across different doses (103, 104, and 105 TCID50). All vaccinated pigs remained healthy with no clinical signs of African swine fever virus (ASFV) infection throughout the 28-day observation period of immunization. VNUA-ASFV-LAVL3 was efficiently cleared from the blood at 14–17 days post-infection, even at the highest dose (105 TCID50). Importantly, the attenuation observed in vivo did not compromise the ability of VNUA-ASFV-LAVL3 to induce protective immunity. Vaccination with VNUA-ASFV-LAVL3 elicited robust humoral and cellular immune responses in pigs, achieving 100% protection against a lethal wild-type ASFV (genotype II) challenge at all tested doses (103, 104, and 105 TCID50). Furthermore, a single vaccination (104 TCID50) provided protection for up to 2 months. These findings suggest that VNUA-ASFV-LAVL3 can be utilized as a promising safe and efficacious LAV candidate against the contemporary pandemic genotype II ASFV.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

African Swine Fever VirusVaccines, AttenuatedAfrican Swine FeverViral VaccinesGenotypeAnimalsSwineAntibodies, ViralCell LineVirulenceVaccination

Stichwörter der Autor:innen

African swine feverefficaciousgenotype IIlive-attenuated virusprotectionsafe

Substanzen

Vaccines, AttenuatedViral VaccinesAntibodies, Viral

Autor:innen und Institutionen

  • Key Laboratory of Veterinary Biotechnology, Faculty of Veterinary Medicine, Vietnam National University of Agriculture, Gia Lam, Ha Noi 12406, Vietnam.
  • Center on Biologics Development and Evaluation, Department of Anatomy and Physiology, College of Veterinary Medicine, Kansas State University, Manhattan, KS 66506, USA.
  • Department of Veterinary Microbiology and Infectious Diseases, Faculty of Veterinary Medicine, Vietnam National University of Agriculture, Gia Lam, Ha Noi 12406, Vietnam.
  • Department of Diagnostic Medicine and Pathobiology, College of Veterinary Medicine, Kansas State University, Manhattan, KS 66506, USA.

ORCID-Profile: Quang Lam Truong, Lihua Wang, Giap Van Nguyen, Huong Lan Thi Lai, Franco Matias-Ferreyra, Jishu Shi

Förderung

  • Vietnam Ministry of Science and Technology
  • National Bio and Agro-Defense Facility Transition Fund, the USDA National Institute of Food and Agriculture
  • USDA ARS Non-Assistance Cooperative Agreements
  • USDA NIFA Award
  • USDA NIFA Subaward
  • National Pork Board Grant
  • Department of Homeland Security

Zitieren

APA

Truong, Q. L., Wang, L., Nguyen, T. A., Nguyen, H. T., Le, A. D., Nguyen, G. V., Vu, A. T., Hoang, P. T., Le, T. T., Nguyen, H. T., Nguyen, H. T. T., Lai, H. L. T., Bui, D. A. T., Huynh, L. M. T., Madera, R., Li, Y., Retallick, J., Matias-Ferreyra, F., Nguyen, L. T., & Shi, J. (2024). A Non-Hemadsorbing Live-Attenuated Virus Vaccine Candidate Protects Pigs against the Contemporary Pandemic Genotype II African Swine Fever Virus. Viruses. https://doi.org/10.3390/v16081326

Vancouver

Truong QL, Wang L, Nguyen TA, Nguyen HT, Le AD, Nguyen GV, et al. A Non-Hemadsorbing Live-Attenuated Virus Vaccine Candidate Protects Pigs against the Contemporary Pandemic Genotype II African Swine Fever Virus. Viruses. 2024. doi:10.3390/v16081326

BibTeX
@article{Truong2024,
  author = {Truong, Quang Lam and Wang, Lihua and Nguyen, Tuan Anh and Nguyen, Hoa Thi and Le, Anh Dao and Nguyen, Giap Van and Vu, Anh Thi and Hoang, Phuong Thi and Le, Trang Thi and Nguyen, Huyen Thi and Nguyen, Hang Thu Thi and Lai, Huong Lan Thi and Bui, Dao Anh Tran and Huynh, Le My Thi and Madera, Rachel and Li, Yuzhen and Retallick, Jamie and Matias-Ferreyra, Franco and Nguyen, Lan Thi and Shi, Jishu},
  title = {A Non-Hemadsorbing Live-Attenuated Virus Vaccine Candidate Protects Pigs against the Contemporary Pandemic Genotype II African Swine Fever Virus},
  journal = {Viruses},
  year = {2024},
  doi = {10.3390/v16081326}
}
Kostenlos starten →